Syremis Therapeutics

About Syremis Therapeutics

Syremis Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel medicines to make a profound impact on mental health care. The company addresses major unmet needs in mental health through a neuropsychiatric pipeline rooted in emerging and clinically validated mechanisms, aiming to improve treatment efficacy and tolerability for conditions like schizophrenia and depression.

Products & Services

ST-905:A potent M1/M4 muscarinic agonist in Phase 1 development for schizophrenia and other serious neuropsychiatric conditions.

ST-901:A novel NMDA antagonist in IND-enabling studies, being developed for major depressive disorder and bipolar depression.

Specialties

Neuropsychiatric drug development Muscarinic M1/M4 agonism NMDA antagonism Mental health treatment

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Series A T: - FT: Series A	A: 165000000 MR: - FA: 165 million FAN: 165000000	D: 2025-12-18 FD: 2025-12-18	6 investors

Series A Latest

2025-12-18

$165.0M

6 investors (Pro only)

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

E

Elisabeth Kogan

CEO and co founder

E

Elena Kagan

Chief Development Officer and co-founder

M

Menashe Levy

Chief Technology Officer and co founder

E

Eli Gendler

Chief Financial Officer

L

Lior Sahaf

VP Business Development

O

Orly Eini

VP of Human Resources

View 10 more team members with Pro

Unlock Full Team Directory

Recent News